Nectar Lifesciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated net loss of ₹29,288.48 lakh for the year ended March 31, 2026, compared to a net loss of ₹6,792.42 lakh in the previous year. The standalone net loss for the period stood at ₹6,791.80 lakh. The results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on May 30, 2026.

The financial statements were published in newspapers on June 1, 2026, complying with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board confirmed that the audit reports do not have any modified opinion. Previous year figures have been regrouped and reclassified where necessary to ensure comparability.

Financial Performance

The table below summarizes the key financial metrics for the standalone and consolidated entities for the quarter and year ended March 31, 2026:

The company reported a total comprehensive loss of ₹6,783.88 lakh on a standalone basis and ₹29,280.56 lakh on a consolidated basis for the financial year. The paid-up share capital stood at ₹1,942.61 lakh with a face value of ₹1 per share.

Earnings Per Share

The basic and diluted earnings per share (EPS) for continuing and discontinued operations reflected the losses incurred during the period. On a consolidated basis, the basic EPS for continuing operations was (₹2.85), while for discontinued operations it was (₹11.72). The total basic EPS for continuing and discontinued operations combined was (₹14.58).

Nectar lifesciences Limited has successfully concluded its income tax assessment litigation with a favorable order from the Deputy Commissioner of Income Tax (DCIT), Chandigarh. The pharmaceutical company announced that the DCIT disposed of the assessment matter for Assessment Year 2017-18 in the company's favor through an order dated March 31, 2026.

Case Background and Timeline

The litigation originated when Nectar Lifesciences challenged notices issued under Sections 148 and 148A(b) of the Income Tax Act, 1961, covering Assessment Years 2017-18 to 2021-22. The company filed a writ petition before the Punjab and Haryana High Court, which directed the Income Tax Department to dispose of the company's objections within eight weeks.

Recent Development Details

The Deputy Commissioner of Income Tax, Central Circle-1, Chandigarh, issued the favorable order for Assessment Year 2017-18 on March 31, 2026. The company received this order via email on April 9, 2026. According to the company's disclosure, this order has no expected financial implications, with the quantum of claims listed as NIL.

Financial Impact and Conclusion

The favorable resolution carries no financial burden for Nectar Lifesciences. The company confirmed that with this latest order, the entire matter stands fully concluded across all contested assessment years.

Disclosure Timeline

The company acknowledged a delay in providing these details to the stock exchanges, attributing it to temporary inaccessibility of a registered email ID of a former employee who had left the organization. Nectar Lifesciences expressed regret for the omission and assured the exchanges of its commitment to furnishing all material information within prescribed time limits in the future.

This successful resolution of the income tax assessment matter removes a potential regulatory overhang for the pharmaceutical company, allowing it to focus on its core business operations without the burden of ongoing tax litigation.